Alnylam Pharmaceuticals, Inc.
NASDAQ:ALNY · NASDAQ Global Select
-$6.27 today
Vol 1.77M · Avg 1.11M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $313.7M +212.8% | -$278.2M +36.8% | -$440.2M +61.1% | -$1.1B -32.6% | -$852.8M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $55.7M -1.8% | $56.7M -41.6% | $97.0M +13.4% | $85.5M -4.6% | $89.7M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$2.2M +97.9% | -$106.8M | $0 | $0 +100.0% | -$55.7M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $348.2M +28.0% | $272.1M +22.7% | $221.7M -3.9% | $230.6M +39.2% | $165.7M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$444.8M -107.8% | -$214.1M -2089.8% | $10.8M +130.3% | -$35.6M +78.2% | -$162.8M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$360.0M -315.9% | -$86.5M +1.6% | -$87.9M -92.9% | -$45.6M +55.2% | -$101.8M | $592.6M | $1.3B | $626.2M |
| Inventory | $8.5M -37.6% | $13.6M -26.0% | $18.4M +153.8% | -$34.1M -29.2% | -$26.4M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $75.1M -17.6% | $91.1M +12.7% | $80.8M -57.8% | $191.8M +117.3% | $88.2M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$168.4M +27.5% | -$232.2M -45522.2% | -$509.0K +99.7% | -$147.6M -20.1% | -$122.8M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $253.4M -3.3% | $261.9M +21.9% | $214.9M -30.5% | $309.2M +77.5% | $174.2M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $524.1M +6405.1% | -$8.3M -108.0% | $104.2M +119.2% | -$541.3M +15.6% | -$641.7M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$58.7M -71.2% | -$34.3M +44.9% | -$62.2M +13.7% | -$72.1M +5.6% | -$76.4M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$1.4B +20.3% | -$1.7B +6.1% | -$1.8B +7.8% | -$2.0B -19.4% | -$1.7B | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $1.8B +14.7% | $1.6B +1.1% | $1.6B -30.4% | $2.2B +52.5% | $1.5B | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $57.6M -0.2% | $57.8M +1401.4% | -$4.4M +66.4% | -$13.2M -202.3% | -$4.4M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $436.3M +473.4% | -$116.8M +65.3% | -$336.4M -298.6% | $169.4M +162.0% | -$273.3M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$546.9M | $0 | $0 -100.0% | $254.0M -49.2% | $500.0M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $250.0M -17.5% | $303.0M +105.4% | $147.5M -43.1% | $259.4M +5.3% | $246.3M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$8.3M +5.9% | -$8.8M -135.6% | $24.7M +128.2% | -$87.6M -117.5% | $500.9M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$305.2M -203.8% | $294.2M +70.9% | $172.1M -59.6% | $425.8M -65.9% | $1.2B | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $34.9M +329.3% | -$15.2M -338.4% | $6.4M +186.0% | -$7.4M +17.6% | -$9.0M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $690.2M +348.8% | $153.8M +386.5% | -$53.7M -215.7% | $46.4M -85.6% | $323.1M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $465.4M +1192.7% | -$42.6M -201.5% | $41.9M +106.8% | -$613.3M +14.6% | -$718.1M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cigna Corporation
NYSE:CI
$74.25B
Regeneron Pharmaceuticals, Inc.
NASDAQ:REGN
$62.16B
argenx SE
NASDAQ:ARGX
$54.47B
Cencora, Inc.
NYSE:COR
$52.84B
Cardinal Health, Inc.
NYSE:CAH
$52.30B
Becton, Dickinson and Company
NYSE:BDX
$52.24B
Edwards Lifesciences Corporation
NYSE:EW
$50.28B
IDEXX Laboratories, Inc.
NASDAQ:IDXX
$44.08B
Zoetis Inc.
NYSE:ZTS
$32.85B
Veeva Systems Inc.
NYSE:VEEV
$24.76B
SEC Filings
Recent regulatory filings
No filings found.
Does ALNY generate free cash flow?
Alnylam Pharmaceuticals, Inc. (ALNY) generated $465.38M of free cash flow in fiscal 2025.
How much operating cash flow does ALNY produce?
Operating cash flow was $524.08M, before capital expenditures of $58.70M.
Explore More
Continue the stock analysis
Jump to another research area for this company.